SecBot SecBot
Insider Cluster (2 insiders) ·Filed Jul 20, 2026

MLTX

MoonLake Immunotherapeutics
BEARISH
Impact 4/10
Horizondays Processed3mo ago
Insider cluster: 2 insiders, $1.7M total
Actionable Insight ▼ Bearish

The simultaneous selling by both C-suite executives at the same price level suggests a coordinated bearish view on near-term prospects, especially given the stock's recent decline. Monitor for any upcoming data readouts or filing events that could trigger further selling. The absence of 10b5-1 plans increases the likelihood of informed trading.

DirectionBearish
Confidencemedium
Horizondays
Final — all horizons settled through T+60d
MLTX ▼ -45.35% at T+60d
SHORT call ✓ call won +45.35% · α vs SPY +50.19% · entry $19.05 → $10.41
Entry = T+0 close
Jul 20, 2026
via day close
T+1d
+5.30%
call -5.30% · α -4.47%
$20.06
settled 3mo ago
T+5d
-0.16%
call +0.16% · α -0.27%
$19.02
settled 3mo ago
T+20d
-14.17%
call +14.17% · α +18.29%
$16.35
settled 2mo ago
T+60d
-45.35%
call +45.35% · α +50.19%
$10.41
settled 13d ago

Price Chart

Loading chart...

Executive Summary

MoonLake Immunotherapeutics (MLTX) CEO and CSO sold a combined $1.69M of shares in open-market transactions over the past week, representing ~0.12% of the $1.4B market cap. This insider selling cluster, though modest in proportion, is notable for involving both C-suite executives simultaneously at the same price level (~$20).

Key Financial Metrics

Direction
selling
Total Value
$1.7M
Insiders
2

Key Facts

  • CEO Santos da Silva Jorge sold 68,300 shares for $1.37M on 2026-07-10 at $20.02
  • CSO Reich Kristian sold 16,105 shares for $322K on 2026-07-15 at $20.01
  • Total insider selling in cluster: $1.69M, 0.12% of market cap
  • Both transactions were open-market sales (code S), no 10b5-1 plan indicated

Financial Impact

Insider selling of $1.69M, modest relative to $1.4B market cap (0.12%)

dilutioninsider ownership

Risk Factors

  • Additional insider selling from other officers or directors
  • Negative clinical trial results or regulatory setbacks for lead pipeline candidate
  • Lack of near-term catalysts could extend selling pressure

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
77% bullish (22 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-MLTX-1784542351848
13 reports for MLTX
Performance horizon
50% Hit rate @ T+60 4 of 8 directional calls Went positive at some point 5 of 11 best @ T+60▲ +39.00%Jun 23, 2026
Filters
Rows
Reports for MLTX — sortable, filterable
TypeNow
Aug 11, 2026
10w ago
Institutional Cluster
BULLISH ★ 5/10
$17.23awaiting T+60—$11.85 (−31.22%)
Aug 10, 2026
11w ago
8-K
BULLISH ★ 7/10
$17.33awaiting T+60—$11.85 (−31.62%)
Aug 10, 2026
11w ago
Press Release
BULLISH ★ 7/10
$17.33awaiting T+60—$11.85 (−31.62%)
Jul 20, 2026
14w ago
Insider Cluster
BEARISH ★ 4/10
$19.05 $10.41▲ +45.35%▲ +50.19%$11.85 (+37.80%)
Jun 25, 2026
17w ago
8-K
BEARISH ★ 6/10
$19.99 $12.39▲ +38.02%▲ +41.87%$11.85 (+40.72%)
Jun 23, 2026
17w ago
Press Release
BEARISH ★ 6/10
$20.00 $12.20▲ +39.00%▲ +42.29%$11.85 (+40.75%)
Jun 22, 2026
18w ago
8-K
BULLISH ★ 7/10
$22.16 $12.20▼ −44.95%▼ −46.69%$11.85 (−46.53%)
Jun 21, 2026
18w ago
Press Release
BULLISH ★ 7/10
$22.16 $12.20▼ −44.95%▼ −46.69%$11.85 (−46.53%)
Jun 11, 2026
19w ago
Institutional Cluster
BEARISH ★ 5/10
$17.75 $15.01▲ +15.44%▲ +19.83%$11.85 (+33.24%)
Jun 1, 2026
21w ago
8-K
NEUTRAL ★ 2/10
$18.82 $15.56▼ −17.32%▼ −18.55%$11.85 (−37.04%)
Showing 10 of 13

US Market Status

Market Closed — Opens in 29m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 20, 2026